One-Year Graft Patency for Elective CABG Affected by Baseline Glycemic Control
Researchers assessed the relationship between 1-year vein graft patency, baseline hemoglobin A1c, and antiplatelet therapy in patients who have received CABG.
Dual Antiplatelet Therapy (DAPT)
Clopidogrel vs Ticagrelor Real-World Efficacy in Patients With ACS Managed With PCI
Differences in mortality and MACE were evaluated in patients with ACS managed with PCI who were receiving ticagrelor or clopidogrel.
Short Dual Antiplatelet Therapy vs De-escalation Following PCI in Patients With ACS
A meta-analysis was conducted to compare short DAPT with de-escalation in patients with acute coronary syndrome who have received percutaneous coronary intervention.
Ticagrelor Without Concomitant Aspirin No Better Than Standard DAPT in PCI
Ticagrelor without aspirin offered no additional benefits compared with conventional dual antiplatelet therapy in patients undergoing PCI for either CAD or ACS.
Genotype-Guided Antiplatelet Therapy Feasible, Effective
Genotype-guided therapy improved outcomes in patients who were CYP2C19 intermediate and poor metabolizers.
Benefits of Changing Dual Antiplatelet Therapy After Acute Coronary Syndrome
Switching DAPT after acute coronary syndrome provides benefits regardless of initial platelet reactivity.
ESC and EACTS Provide New Dual Antiplatelet Therapy Guidelines in Coronary Heart Disease
The European Society of Cardiology and European Association for Cardio-Thoracic Surgery have released a focused update on dual antiplatelet therapy use in coronary heart disease.
Dual Antiplatelet Therapy vs Aspirin Alone Post-CABG in Diabetes
No significant differences were observed between dual antiplatelet therapy and aspirin alone following coronary artery bypass grafting in patients with diabetes.
Revisiting Necessity of Full Dose Triple Therapy With DAPT for Routine PCI
All-cause death plus hospitalization possibly from bleeding were reduced in both rivaroxaban groups compared with the reference group.
Long-Term DAPT Reduced MACE After Complex PCI
Long-term dual antiplatelet therapy was associated with reduced MACE in patients who underwent complex percutaneous coronary intervention.
- Loading...
Loading...
Loading... 
Loading...